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Genetic diversity, transmission 
dynamics and drug resistance of 
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Carla Silva1, Isabel Couto3, Miguel Viveiros3, Nuno Taveira1,4,* & Isabel Portugal1,*
Tuberculosis (TB) poses a serious public health problem in Angola. No surveillance data on drug 
resistance is available and nothing is known regarding the genetic diversity and population structure 
of circulating Mycobacterium tuberculosis strains. Here, we have genotyped and evaluated drug 
susceptibility of 89 Mycobacterium tuberculosis clinical isolates from Luanda. Thirty-three different 
spoligotype profiles corresponding to 24 different Shared International Types (SIT) and 9 orphan 
profiles were detected. SIT 20 (LAM1) was the most prevalent (n = 16, 18.2%) followed by SIT 42 (LAM9; 
n = 15, 17.1%). Overall, the M. tuberculosis population structure in this sample was dominated by LAM 
(64.8%) and T (33.0%) strains. Twenty-four-loci MIRU-VNTR analysis revealed that a total of 13 isolates 
were grouped in 5 distinct clusters. Drug susceptibility data showed that 22 (24.7%) of the 89 clinical 
isolates were resistant to one or more antibacillary drugs of which 4 (4.5%) were multidrug resistant. 
In conclusion, this study demonstrates a high predominance of LAM strains circulating in the Luanda 
setting and the presence of recent transmission events. The rate and the emergence dynamics of drug 
resistant TB found in this sample are significant and highlight the need of further studies specifically 
focused on MDR-TB transmission.
Despite the importance that the African region plays in a global TB epidemiological context, many countries still 
lack data on the prevalence of specific M. tuberculosis strains and drug resistance1. This is the case for Angola, 
which presently lacks any data concerning drug resistance rates and prevalence of specific Mycobacterium tuber-
culosis genotypes and respective population structure. The latest World Health Organization (WHO) estimates 
for Angola suggest the occurrence of 90 000 new cases and an incidence rate of 370 cases per 100 000 habitants in 
2014 combined with an increasing trend over the last two decades1. Furthermore, these estimates point towards 
the occurrence of 1500 cases of multidrug resistant (MDR) TB that were not yet bacteriologically confirmed1.
The situation is particularly concerning in Luanda, the capital city of Angola, and its province, which accounts 
for approximately one-third of the country’s TB cases (21 281 cases notified in 2013)2,3.
Understanding how TB transmission takes place is a key component to strategically manage TB from a public 
health perspective4–6. Furthermore, given the unexpected degree of genetic diversity more recently unveiled by 
whole genome sequencing and since different strains have the ability to elicit distinct immunopathological events, 
tracking specific strains plays an even more important role7–10. Several typing methods have been developed over 
the past decades to investigate the clonality, population structure and transmission of M. tuberculosis5,11–14. These, 
have gradually led to the development of online databases and have enabled the identification of epidemiologi-
cally links between patients and risk factors that otherwise would be nearly impossible to identify with the use of 
traditional epidemiological investigation and contact tracing6,15,16.
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Currently, there is no data concerning M. tuberculosis diversity, population structure and drug resistance in 
Angola. Herein, we have characterized the genetic diversity and drug susceptibility profiles of circulating M. 
tuberculosis strains recovered from patients followed at a central hospital in Luanda.
Methods
Patients and Clinical Isolates. A total of 106 sputum samples, positive for sputum smear acid-fast bacilli, 
were collected from patients clinically diagnosed with TB in Hospital da Divina Providência (HDP) in Luanda 
district. HDP is located in the Kilamba-Kiaxi municipality and serves an estimated population of 990 892 inhab-
itants. Regarding TB treatment, HDP has a unit dedicated to the diagnosis of respiratory diseases (approximately 
600 new TB cases/year) and directly observed treatment. Sample collection was performed between March to 
June 2014, where all sputum smear positive samples, comprising approximately 18% of the hospitals yearly diag-
nosed cases, were collected to avoid unbiased selection criteria. Patients’ demographical and clinical data were 
collected from clinical records. The study was approved by the Angolan Ministry of Health’s Ethics Committee, 
and all methods were performed in accordance with the relevant guidelines and regulations, including informed 
consent from all patients enrolled in the study.
Sputum sample decontamination was carried out using the NaOH/N-acetyl-L-Cysteine method and cultured 
on Lowenstein-Jensen slants and Middlebrook 7H9 medium supplemented with oleic acid, albumin, dextrose 
and catalase (OADC) and an antibiotic cocktail comprised by carbenicillin (final concentration: 5 μ g/ml), tri-
methoprim (15 μ g/ml), amphotericin B (1 μ g/ml) and polymyxin B (20 U/ml).
High molecular weight genomic DNA was extracted from mycobacterial grown on Lowenstein-Jensen media 
by the cetyltrimethylammonium bromide (CTAB) method17.
All isolates were identified as belonging to the M. tuberculosis complex by positive PCR amplification of an 
internal IS6110 fragment17.
Drug Susceptibility Testing (DST). All M. tuberculosis complex isolates were tested for first-line DST 
to all first-line antibacillary drugs (isoniazid (INH), rifampicin (RIF), ethambutol (EMB), streptomycin (STP) 
and pyrazinamide (PZA)) through the BACTEC™ MGIT™ 960 system (Becton Dickinson Diagnostic Systems, 
Sparks, MD, USA) using the standardized procedure according to the manufacturer’s instructions18.
Spoligotyping and MIRU-VNTR typing. Spoligotyping was performed as described previously by 
Kamerbeek et al.12. Detection of the hybridization patterns was carried out using the ECL® Chemiluminescence 
Detection System (GE Healthcare®, Cleveland, OH, USA).
All isolates were typed by 24-loci MIRU-VNTR using the multiplex amplification procedure described by 
Supply et al.11.
Spoligotyping and MIRU-VNTR profiles were assigned to lineage, clade, shared international type (SIT) and 
MIRU International Type (MIT) using the SITVIT WEB international database (http://www.pasteur-guadeloupe.
fr:8081/SITVIT_ONLINE/index.jsp) and/or the SPOTCLUST tool (http://tbinsight.cs.rpi.edu/run_spotclust.
html)16,19.
A dendrogram was constructed based on the MIRU-VNTR and spoligotyping data, as appropriated, using the 
MIRU-VNTRplus international database15. A cluster was defined as group of two or more strains with identical 
profile. The Hunter-Gaston index of diversity was computed as described previously20.
A minimum spanning tree was also constructed using the MIRU-VNTRplus database to investigate phyloge-
netic relationships within the sample and identify clonal complexes. A clonal complex was defined as groups of 
isolates that are within dual-locus variants of each other.
All statistical analyses were conducted using the IBM© SPSS© Statistics v.21 (IBM Corporation, Armonk, NY, 
USA).
Results
Patients and Clinical Isolates. In the present study we have collected 106 sputum samples, positive for 
acid-fast bacilli, in HDP in 2014. After culture and identification, five samples were excluded due to contamina-
tion; seven samples were duplicated from the same patient; and, five samples showed no growth after a 3 month 
incubation period. The remaining samples yielded 89 M. tuberculosis complex clinical isolates, each correspond-
ing to a different patient (Fig. 1).
It was only possible to collect partial demographical and clinical data for 60 (67.4%) of the 89 studied patients 
(see Supplementary Table 1). The majority of the patients resided in the Kilamba-Kiaxi municipality (n = 34/58, 
58.6%), where HDP is located, followed by a significant proportion of patients living in Viana (n = 19/58, 32.8%) 
(Supplementary Table 1).
The majority of the patients comprising this sample were registered as new patients (n = 53/60, 88.3%), 
approximately half presented with cavitary lung disease (n = 29/50, 58.0%) and eight out of 55 patients (14.5%) 
were co-infected with HIV. Fifty-one (87.9%) out of 58 patients started the 2HRZE/4HR treatment regimen while 
the remaining seven started the 2HRZES/4HR treatment regimen. The majority of the patients (n = 39/60, 65.0%) 
achieved both bacteriological and clinical cure after completing the treatment regimen (Supplementary Table 1).
Drug Resistance. We have detected eight different drug-resistance profiles and overall, 22 (24.7%) isolates 
showed resistance to one or more antibacillary drugs (Table 1). Four (4.5%) isolates exhibited a multidrug resist-
ant (MDR) profile, i.e. resistance to at least isoniazid (INH) and rifampicin (RIF), whereas 13 of the 22 drug 
resistant isolates were resistant to INH or RIF and can thus be considered pre-MDR-TB isolates.
Population structure and Molecular Epidemiology. To gain insight on the sample’s population 
structure all strains were genotyped by spoligotyping and 24-loci MIRU-VNTR. One isolate (HDP7743) 
www.nature.com/scientificreports/
3Scientific RepoRts | 7:42814 | DOI: 10.1038/srep42814
showed double alleles in 5 of the 24 MIRU-VNTR loci and was therefore excluded from the genotypic analysis. 
Spoligotyping analysis of the remaining 88 M. tuberculosis isolates enabled the detection of 33 different spoli-
gotype profiles corresponding to 24 different Shared International Types (SIT) and 9 orphan profiles (Table 2, 
Fig. 2). SIT 20 (LAM1) was the most prevalent SIT found (n = 16, 18.2%) followed by SITs 42 (LAM9; n = 15, 17. 
1%) and 53 (T1; n = 12, 13.6%).
Comparatively, the 24-loci MIRU-VNTR analysis showed, as expected, a superior discriminatory power in 
which only 13 isolates were clustered across 5 clusters (Fig. 2, Table 2). Analysis of the genotypic data using the 
12, 15 and 24-loci MIRU-VNTR sets showed that the 15- and 24-loci sets had comparable discriminatory ability 
as illustrated by the comparable values of the Hunter-Gaston Index of diversity (D) (Table 3)20,21. Both spoligotyping 
and 12-loci MIRU-VNTR, owing to a lesser capability of genotypic discrimination, yielded a high degree of cluster-
ing, which does not necessarily illustrate recent transmission events but rather be associated with an earlier common 
origin followed by diversification at the genotypic level, in particular at loci with a faster molecular clock11.
Figure 1. Flowchart illustrating the selection of the studied sample of M. tuberculosis clinical isolates and, 
main results from drug susceptibility testing and genotyping. From the 106 sputum samples positive for 
acid-fast bacilli, 7 were excluded since they were duplicates from the same patient, 5 were contaminated and 
another 5 showed no growth, leaving a total of 89 M. tuberculosis clinical isolates. Drug susceptibility testing 
revealed that 22 isolates were resistant to one or more antibacillary drugs, of which four corresponded to 
MDR-TB isolates. Genotyping analysis allowed the identification of 13 clustered isolates across five different 
MIRU-VNTR clusters with one isolate excluded due to mixed strain infection. Spoligotyping analysis revealed a 
population structure dominated mostly by LAM and T strains.











Table 1.  First-line drug resistance profiles found among the 89 studied isolates. 1Resistance profile: I, 
isoniazid; R, rifampicin; S, streptomycin; E, ethambutol; P, pyrazinamide.
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Drug resistant isolates were found across distinct clades and MIRU-VNTR clusters although the largest 
MIRU-VNTR cluster detected (n = 5) harboured 3 drug resistant isolates, including one MDR isolate (Fig. 1). A 
two-isolate cluster composed by pre-MDR strains (mono-INH resistance) was also detected.
To better understand transmission, a minimum spanning tree was constructed using double-locus variants from 
24-loci MIRU-VNTR data as a maximum distance to link and define clonal complexes (Fig. 3). We have identified 12 
clonal complexes which ranged in size from two to 17 isolates. The largest clonal complex, CC1, was comprised by 17 
LAM isolates, mostly belonging to the LAM1 clade and MIT10 (Supplementary Table 2). A second large LAM9 clonal 
complex, CC2, was also detected comprised by six isolates. T strains were mostly detected on three clonal complexes, 
CC3–6, comprised by 6, 5 and 4 isolates, respectively. Furthermore, 32 singleton profiles were identified (Table 4).
Next, we have combined the genotypic data with the geographical data, i.e. patient residency area. Geographical 
case dispersion analysis was restricted to the Kilamba-Kiaxi and Viana since all but 5 patients resided in these munic-
ipalities. This is expected since HDP is located in the eastern zone of Kilamba-Kiaxi, near the Viana municipality and 
primarily serves these two municipalities. Although not meeting statistical significance, genotypic dispersion through 
these municipalities appears to exhibit substantial differences for some of the clades or clonal complexes assessed by 
spoligotyping or MIRU-VNTR, respectively (Table 5). Generally, LAM strains were more prevalent in Kilamba-Kiaxi 
in comparison to the Viana municipality (LAM: 70.59% vs 42.11%, respectively), which consequently holds a higher 
percentage of T strains (52.63%). Stratification by clonal complex, clade and SIT allowed picturing the distribution of 
these genetic groups at a finer resolution: in Kilamba-Kiaxi CC1 stands out as the most prevalent MIRU-VNTR clonal 
complex, which correlates with a high SIT20/LAM1 prevalence in this municipality (Table 5). CC3 also appears to play 
an important role in Kilamba-Kiaxi’s epidemiological context, consistent with the prevalence of T1 strains. Although 
no clonal complex appears to be more prevalent in Viana, SIT53/T1 and SIT42/LAM9 strains exhibited a higher 
prevalence in this setting than in Kilamba-Kiaxi (Table 5).
Spoligotyping
No. Isolates (%)SIT Clade Octal Code
635 LAM3 000000007560771 2 (2.27)
Orphan LAM1/LAM9 601777607760771 1 (1.14)
Orphan LAM1/LAM9 676777607760731 1 (1.14)
2271 LAM2 677717607760771 1 (1.14)
194 LAM2 677737607760731 1 (1.14)
1755 LAM6 677777607560771 1 (1.14)
1321 LAM1/LAM4 677777607760731 1 (1.14)
20 LAM1 677777607760771 16 (18.18)
Orphan T3/X3 700003607560371 1 (1.14)
1894 LAM9 747777607760771 1 (1.14)
144 T1 770000003760771 5 (5.68)
2073 LAM3 776000607760771 1 (1.14)
33 LAM3 776177607760771 1 (1.14)
1535 LAM9 777577607760771 1 (1.14)
1548 LAM8 777703400000360 2 (2.27)
Orphan T1 777737737760731 1 (1.14)
Orphan LAM9 777777405720771 1 (1.14)
Orphan T1 777777557560771 1 (1.14)
Orphan T1 777777577740371 1 (1.14)
74 T1 777777600160771 1 (1.14)
Orphan LAM9 777777601460771 1 (1.14)
306 T1 777777601560771 1 (1.14)
290 LAM8 777777606760771 1 (1.14)
95 LAM6 777777607560731 1 (1.14)
64 LAM6 777777607560771 3 (3.41)
1530 LAM4 777777607760711 1 (1.14)
60 LAM4 777777607760731 3 (3.41)
42 LAM9 777777607760771 15 (17.05)
Orphan LAM10 777777740160771 1 (1.14)
2025 Haarlem3/T1 777777777700371 1 (1.14)
244 T1 777777777760601 6 (6.82)
52 T2 777777777760731 1 (1.14)
53 T1 777777777760771 12 (13.64)
Total 88 (100)
Table 2.  Number of isolates found in the present study by SIT and clade.
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Figure 2. MIRU-VNTR dendrogram (24 loci) of the 88 M. tuberculosis clinical isolates analysed in  





D 0.973 0.993 0.996 0.915
No. of clusters 17 5 5 9
No. of clustered isolates 53 15 13 64
Table 3.  Comparison of various diversity estimators across different MIRU-VNTR loci sets and 
spoligotyping. 1D – Hunter-Gaston Index of diversity.
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Discussion
In the present study we made the first characterization of the genetic diversity and drug resistance of M. tuber-
culosis complex strains circulating in Luanda, Angola’s most important setting concerning TB epidemiology2.
Drug susceptibility testing revealed a worrying situation concerning resistance rates. Approximately 
one-quarter of the studied isolates were resistant to one or more antibacillary drugs. This situation is particu-
larly notorious for INH resistance which was detected on 18% of the clinical isolates. Pre-MDR-TB strains (i.e. 
monoresistant to INH or RIF) were found to represent 14.6% of the studied samples highlighting an increased 
potential for MDR-TB development during the course of treatment by resistance amplification due to stand-
ardized treatment regimens and particularly, in cases of poor adherence22,23. The potential risk for resistance 
amplification is well patent in the Lisboa3 and Q1 strains in Portugal, or the KZN strains in South Africa that 
have gradually acquired resistance to an increasing number of drugs over the years in a stepwise manner8,24,25. 
Also, the MDR-TB rate appears to be moderate (4.5%) but may in fact represent a serious problem from a public 
health perspective. Assuming that the rate found in this study is the same across the entire province setting, new 
MDR-TB cases can be estimated to be at least around 958 cases based on the official province data estimate for 
2013, of 21 281 new cases/year2. This situation clearly contrasts with the data reported in a study conducted in the 
Ndola district, in Zambia, a neighbouring country, in which from 193 clinical isolates only 8.8% and 0.5% showed 
resistance to any antibacillary drug or MDR, respectively26. A clear example of the consequences of not having 
an adequate laboratory support on the follow up of TB patients under treatment, a recurrent situation in many 
countries with unreported high levels of acquired MDR-TB27–29.
Besides drug resistance we also investigated the M. tuberculosis genetic diversity, population structure and 
transmission dynamics. Genotypic analysis through spoligotyping and 24-loci MIRU-VNTR revealed a popu-
lation structure dominated by LAM and the ill-defined T strains. Comparing our data with the recently pub-
lished global framework for the LAM lineage proposed by Mokrousov et al.30 and the SNP barcode system for 
phylogenetic classification proposed by Coll et al.10, we find that: (i) the single strain belonging to SIT33 exhibits 
the VNTR signature characterized by loci 2401_2 and 3171_1 alleles in agreement to what has been proposed 
previously; (ii) 11 (12.5%) isolates bearing LAM or possibly LAM-derived spoligotype profiles formed a mono-
phyletic clade bearing the locus 154_1 allele, characteristic of the RD115-sublineage/sublineage 4.3.3; 44 (50.0%) 
isolates bearing LAM profiles were found to exhibit the VNTR locus 802_1 allele proposed to be a marker for 
the RD174-sublineage/sublineage 4.3.410,30. The data herein, presented therefore contributes to the VNTR data 
available for sub-Saharan Africa and is consistent with an increasing LAM prevalence when moving southwards 
on the African continent30.
Figure 3. Minimum spanning tree of the 88 M. tuberculosis clinical isolates studied herein. The tree was 
constructed based on 24-loci MIRU-VNTR genotypic data and clonal complexes defined as MIRU-VNTR 
profiles within double-locus variants of each other. Clonal complexes have been highlighted and annotated on 
the tree (CC1-12) along with each node SIT, whenever each node is composed by strains of the same SIT and 
the spoligotype profile is not orphan. Numbers on the lines connecting each node indicate the loci difference 
between each node.
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It is also important to consider when structuring M. tuberculosis samples by spoligotyping clades that spol-
igotyping profiles show a tendency to converge and that a given clade does not necessarily share a more recent 
common ancestor. Such is particularly true, e.g., among the ill-defined T lineage and LAM9 clade10. From a public 
health standpoint such polyphyletic clades may therefore enclose a higher degree of genetic diversity and under-
pin distinct transmission networks.
Again, when comparing with the neighbouring countries, only Zambia and Namibia have sufficient data on 
SITVIT WEB database to allow such comparison, as the M. tuberculosis population structure in the Democratic 
Republic of the Congo is presently unknown16. While Zambia exhibits a more diverse population structure dom-
inated by the LAM11-ZWE (not found in the present study) but including other LAM, CAS, MANU and EAI 
strains, Namibia exhibits a more restricted diversity mainly dominated by SIT 20 (LAM1) strains that account to 
78.5% of the strains deposited in SITVIT WEB for this country16. Although we cannot rule out epidemiological 
influence from the Democratic Republic of the Congo in the Angolan population structure, for Zambia there is 
no data supporting any epidemiological influence in Angola since no LAM11-ZWE strains were found in our 
sample. On the other hand, Namibia’s M. tuberculosis population structure might be or have been of importance 
in shaping the current Angolan epidemiological context concerning genetic diversity as the most prevalent SIT 
in Namibia (SIT 20) was also the most prevalent SIT in our study albeit with a significant difference in preva-
lence (78.5% vs 18.2%, respectively). The relations that both countries have maintained during the Angolan civil 
war might have been of particular importance in strain circulation between both countries as a peak of 30 881 
Angolan citizens took refuge in Namibia in 2001, most of which have later returned to the country of origin31. 
Similarly, the Democratic Republic of the Congo, for which no data on the M. tuberculosis genetic diversity pres-
ently exists, hosted up to 186 879 Angolan refugees in the same period, which is likely to have influenced the 
M. tuberculosis population structure on both countries. Strain spreading from the Democratic Republic of the 
Congo, and eventually from Republic of Congo, is plausible given the documented spread of HIV-1 variants from 
these countries to Angola32.
However, another factor shaping the population structure found herein might be located further away, per-
taining the Community of Portuguese Speaking Countries. In fact a very similar M. tuberculosis population struc-
ture is found in Portugal when it comes to the prevalence of LAM strains16. All SIT20/LAM1 isolates (n = 16, 
18.2%), and derived SITs, bear the VNTR locus 2461_2 allele while Lisboa3 clade strains in Portugal harbour 
the 2461_1 allele, which on the one hand hampers the establishment of a more direct link but, on the other 
hand, makes it possible to hypothesize that Lisboa3 strains might have derived from such SIT20/LAM1 strains 
bearing the 2461_2 allele during its evolutionary trajectory towards XDR-TB8,30. Such hypothesis warrants, how-
ever, further studies as the SIT20/LAM1 strains found in this study might have originated in Latin America as 
well16,30. Furthermore, 13 (18.8%) isolates were also found to harbour the VNTR locus 1644_1_allele that accord-
ing to Mokrousov et al.30 is only observed in few isolates across the RD174-sublineage with the exception of Q1 
(SIT1106/LAM4) clade strains. This latter finding also raises the hypothesis of a common evolutionary origin 
between these strains, and countries, that merits further investigation8,30. Historical ties connect the Community 
of the Portuguese Speaking Countries, which likely favour, at a macroepidemiological level, an enhanced strain 
circulation between these countries.
There is some paucity of data concerning clustering rates in African countries. The clustering rates obtained 
in this study, particularly with the 15 or 24-loci MIRU-VNTR sets, are comparable with the ones reported by 
Homolka et al.33 in a study involving strains from Sierra Leone but considerably lower than the clustering rates 
obtained by Mulenga et al.34 in a study from Ndola district in Zambia33,34. It is also likely that the clustering rate 
in our study might be underestimated due the restricted sampling timeframe34. Overall, the population structure 
provided by MIRU-VNTR typing was consistent with the spoligotyping population structure. Nevertheless, as 
Clonal Complex Isolates No. of Isolates (%) Clade (No. of Isolates)
CC1
HDP7609, HDP7626, HDP7732, HDP8633, HDP9020, 
HDP7609, HDP8819, HDP7689, HDP7816, HDP7955, 
HDP8014, HDP8644, HDP7735, HDP8628, HDP7603, 
HDP7984, HDP7900, HDP7731
17 (19.3) LAM1 (16), LAM6 (1)
CC2 HDP9025, HDP7630, HDP7942, HDP7844, HDP7768, HDP7870 6 (6.8) LAM9 (5), LAM8 (1)
CC3 HDP8643, HDP7766, HDP7687, HDP7718, HDP8053, HDP7893 6 (6.8) T1 (5), LAM10 (1)
CC4 HDP8044, HDP7909, HDP8039, HDP8784, HDP7702 5 (5.6) T1 (5)
CC5 HDP7980, HDP8788, HDP7503, HDP8627 4 (4.5) T1 (4)
CC6 HDP7753, HDP8033, HDP7737 3 (3.4) LAM9 (2), LAM6 (1)
CC7 HDP7707, HDP7680, HDP8859 3 (3.4) LAM1 (1), LAM2 (1), LAM9 (1)
CC8 HDP8796, HDP7711 2 (2.3) T1 (1), Haarlem3/T1 (1)
CC9 HDP8045, HDP8015 2 (2.3) T1 (2)
CC10 HDP8719, HDP7874 2 (2.3) T3/X3 (1), LAM6 (1)
CC11 HDP8814, HDP8764 2 (2.3) LAM3 (2)
CC12 HDP7803, HDP7937 2 (2.3) LAM9 (2)
Table 4.  Clinical isolates present in each clonal complex defined as groups of 24-loci MIRU-VNTR profiles 
within double-locus variants of each other.
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reported previously, MIRU-VNTR allows a deeper discrimination between isolates and is therefore more ade-
quate for epidemiological surveillance11. Still in this regard, no significant difference exists between the discrim-
inatory ability of 24 vs the 15 MIRU-VNTR loci sets as measured by the Hunter and Gaston Index of Diversity 
(0.996 vs 0.993, respectively) for this setting. For routine epidemiological surveillance the 15-loci set is therefore 
recommended with the 24-loci set being more adequate for M. tuberculosis phylogenetic studies, as proposed by 
Supply et al.11.
Genotypic Group
No. of Isolates (%)
Kilamba-Kiaxi Viana
Clonal Complex1
 CC1 (LAM1) 9 (26.47) 3 (15.79)
 CC2 (LAM9) 2 (5.88) 2 (10.53)
 CC3 (T1) 5 (14.71) 1 (5.26)
 CC4 (T1) 1 (2.94) 2 (10.53)
 CC5 (T1) 1 (2.94) 1 (5.26)
 CC6 1 (2.94) 0 (0)
 CC7 1 (2.94) 0 (0)
 CC8 1 (2.94) 0 (0)
 C9 (T1) 0 (0) 2 (10.53)
 CC10 1 (2.94) 0 (0)
 CC11 (LAM3) 12 (35.29) 8 (42.11)
 Total 34 (100) 19 (100)
Clade
 HAARLEM3/T1 1 (2.94) 0 (0)
 LAM1 9 (26.47) 2 (10.53)
 LAM1/LAM9 1 (2.94) 0 (0)
 LAM10 1 (2.94) 0 (0)
 LAM3 2 (5.88) 0 (0)
 LAM4 2 (5.88) 1 (5.26)
 LAM6 2 (5.88) 1 (5.26)
 LAM8 2 (5.88) 0 (0)
 LAM9 5 (14.71) 4 (21.05)
 T1 9 (26.47) 9 (47.37)
 T2 0 (0) 1 (5.26)
 T3/X3 0 (0) 1 (5.26)
 Total 34 (100) 19 (100)
SIT
 144 1 (2.94) 2 (10.53)
 1530 0 (0) 0 (0)
 1548 1 (2.94) 0 (0)
 1894 0 (0) 0 (0)
 20 9 (26.47) 2 (10.53)
 2025 1 (2.94) 0 (0)
 244 2 (5.88) 2 (10.53)
 290 1 (2.94) 0 (0)
 306 0 (0) 1 (5.26)
 33 1 (2.94) 0 (0)
 42 4 (11.76) 4 (21.05)
 52 0 (0) 1 (5.26)
 53 4 (11.76) 3 (15.79)
 60 2 (5.88) 1 (5.26)
 635 1 (2.94) 0 (0)
 64 1 (2.94) 1 (5.26)
 95 1 (2.94) 0 (0)
 Orphan 5 (14.71) 2 (10.53)
 Total 34 (100) 19 (100)
Table 5.  Distribution of genotypic groups, MIRU-VNTR Clonal Complexes and SIT, through the 
Kilamba-Kiaxi and Viana municipalities. 1Spoligotyping clade in brackets was added to clonal complexes 
whenever these were composed by a clear majority of a specific clade.
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Besides demonstrating the presence of recent transmission events, complex transmission chains with a com-
mon origin may be underlying local strain diversification. In particular, the genotypic diversification exhibited by 
CC1, in comparison with the other clonal complexes, and its association with SIT20/LAM1 clades suggest an ear-
lier introduction of LAM1 strains in this setting when compared with other clade-associated clonal complexes of 
restricted genotypic diversification. Concerning its global importance, SIT20/LAM1/MIT10 strains have already 
been previously described in Portugal as associated with drug resistance, highlighting, again, the putative epide-
miological links between Portuguese-speaking countries8.
Additionally, given the high number of singleton profiles and non-clustered isolates, another important aspect 
to consider is that TB reactivation may be playing an important role in this setting’s TB epidemiology. Tackling 
TB by preventive treatment on specific sub-populations associated with known risk factors for disease reactiva-
tion may contribute to slowing down the country’s increasing TB incidence35.
In conclusion, this first cross-sectional study conducted in Luanda, Angola, provides a framework for future 
studies and programmatic management of TB in Angola. We provide sufficient evidence for cluster-based trans-
mission with differential geographic dispersion. Furthermore, the moderate rate of MDR-TB found in this sample 
has major public health implications and highlights the need for further studies specifically focused on MDR-TB 
transmission.
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